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Abstract
Objective: To evaluate the efficacy of an individualised tailored lifestyle intervention on physical activity, dietary intake,
smoking and compliance to statin therapy in people with Familial Hypercholesterolemia (FH).
Methods: Adults with FH (n = 340) were randomly assigned to a usual care control group or an intervention group. The
intervention consisted of web-based tailored lifestyle advice and face-to-face counselling. Physical activity, fat, fruit and
vegetable intake, smoking and compliance to statin therapy were self-reported at baseline and after 12 months. Regression
analyses were conducted to examine between-group differences. Intervention reach, dose and fidelity were assessed.
Results: In both groups, non-significant improvements in all lifestyle behaviours were found. Post-hoc analyses showed a
significant decrease in saturated fat intake among women in the intervention group (b=21.03; CI 21.98/20.03). In the
intervention group, 95% received a log on account, of which 49% logged on and completed one module. Nearly all
participants received face-to-face counselling and on average, 4.2 telephone booster calls. Intervention fidelity was low.
Conclusions: Individually tailored feedback is not superior to no intervention regarding changes in multiple lifestyle
behaviours in people with FH. A higher received dose of computer-tailored interventions should be achieved by uplifting
the website and reducing the burden of screening questionnaires. Counsellor training should be more extensive.
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Introduction
Familial hypercholesterolemia (FH) is an autosomal dominant
disorder of the lipoprotein metabolism. Due to a defect of the low
density lipoprotein (LDL) receptor gene, plasma concentrations of
LDL cholesterol (LDL-C) are elevated [1]. In most Western
countries, approximately one in 500 people is affected with FH
[2]. Elevated serum LDL-C and therefore FH is associated with an
elevated risk of premature cardiovascular disease (CVD) [3],
which is the disease with the highest burden in disability adjusted
life years in the Netherlands [4]. If elevated LDL-C is not
diagnosed and treated, the cumulative risk of developing coronary
artery disease by the age of 60 years is over 60% for men, and over
30% for women [5].
Yet, research has mainly been focused on the effectiveness of
pharmaceutical therapy, whereas achieving (additional) improve-
ment by lifestyle change has hardly been investigated in people
with FH. Large primary and secondary prevention trials with
statins have clearly demonstrated the benefit of reducing LDL-C
in subjects with high LDL-C [6,7]. Also, Versmissen and
colleagues showed an overall risk reduction in a large cohort
(n = 2146) of people with FH that used statins [8]. However,
lifestyle factors also appear to play an important role in
moderating the course of FH [9,10]. The EUROASPIRE III
survey, conducted in 2006–2007 in 22 European countries,
showed a high prevalence of unhealthy lifestyles among CVD
patients treated by cardiologists, and moreover, use of medication
was often inadequate to achieve treatment goals [11]. Overall, two
main strategies are of importance to optimally reduce CVD risk
among people with FH: 1) Improvement of compliance to statin
therapy, and 2) Improvement of CVD-risk-related lifestyle.
A healthy lifestyle is mentioned as an aspect of the treatment of
FH with many benefits beyond LDL-C-lowering drugs [12]. In the
most recent European guidelines on cardiovascular disease
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prevention [13], lifestyle modification is recommended for
individuals at high risk for CVD. Results of primary prevention
trials in high-risk persons and secondary prevention trials in CVD
patients both show that substantial reductions in the CVD risk can
be obtained through lifestyle changes [14–15]. For example, the
INTERHEART study showed that eating fruit and vegetables
daily, being physically active regularly and avoiding smoking were
effective in reducing the risk of a myocardial infarction by 80%
[16]. Particularly, interpersonal and tailored interventions match-
ing an individual’s specific needs and preferences have shown
promising results within a range of lifestyle behaviours [17,18].
There is a lack of evidence-based interventions that incorporate
a comprehensive approach to optimise treatment goals of people
with FH in the Netherlands, as well as elsewhere. We assume that
lifestyle improvements can positively change biological CVD risk
indicators, and that this would eventually lead to a reduction of the
CVD risk. In the PRO-FIT project, we developed an individually
tailored lifestyle intervention aimed at a CVD risk reduction in
individuals with FH. At first, we investigated the efficacy of the
intervention on biological CVD risk indicators: lipids (LDL-C,
HDL-C, TC and triglycerides), systolic blood pressure, glucose,
body mass index (BMI) and waist circumference [19]. In this
paper, we report the efficacy on smoking, physical activity, dietary
intake and compliance to statin therapy.
Materials and Methods
Design and participants
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. A parallel randomised controlled trial was conducted
with measurements at baseline and at 12 months post-baseline.
Participants diagnosed with FH through DNA analyses from
January 1st 2007 to April 15th 2009, aged from 18 to 70 years and
with a LDL-level.75th percentile (age and gender specific) were
recruited from the national cascade screening program of the
Foundation for the Identification of Persons with Inherited
Hypercholesterolemia (StOEH) [20]. Access to internet, sufficient
fluency in Dutch and residency ,150 km radius from Amsterdam
were additional eligibility criteria. Invitation brochures were send
by a research assistant to 986 people during six months (from
February 1st 2009 until August 1st 2009) and resulted in 340
participants (34%), of whom 336 (99%) completed the baseline
questionnaire, and 318 (94%) completed the baseline and follow-
up questionnaire. The follow-up period of 12 months lasted until
August 2010. Details on recruitment and participant flow can be
found in figure S1. Details on power calculation can be found
elsewhere [21].
The content of this paper was guided by the recommendations
for reporting randomised controlled trials of the CONSORT
(Consolidated Standards of Reporting Trials) statement [22]. The
PRO-FIT project was approved by the Medical Ethics Committee
of the VU University Medical Centre (under registration number:
NL23932.029.08) and all participants gave written informed
consent. The trial is registered at the Dutch Trial Register (under
registration number: NTR1899).
Procedure
After the participant had confirmed to participate and had
signed the informed consent form, the baseline questionnaire was
sent out. Thereafter, the concealed randomisation procedure was
carried out by an independent researcher. Participants were
randomly assigned to either the usual care control group (n= 159)
or the intervention group (n= 181) through a stratified comput-
erised randomisation procedure using Microsoft Office Access
2003 software. At first, participants were stratified according to
cholesterol lowering medication use, assuming that medication use
implicates treatment by a general practitioner and/or medical
specialist, who could have already given lifestyle advice. In
addition, we expected that a decrease in LDL-C – the primary
outcome of this project - because of the intervention is smaller if a
participant already uses medication. Family members of the same
household were clustered and subsequently randomised as a
cluster to prevent contamination of the intervention effect due to
spill over of communication about the intervention among
participants. For this reason, the allocation ratio was 1:1.1.
Theoretical framework
The intervention of the PRO-FIT project was developed
according to the integrated model for exploring motivational
and behavioural change, the I-Change model (2.0) [21,23]. Briefly,
it assumes that the behavioural change process can be distin-
guished in three phases: awareness, motivation and action/
behaviour. Hypothetically, due to gained knowledge and aware-
ness of one’s CVD risk, a participant will become motivated to
change lifestyle behaviour(s), and subsequently, implementation
intentions and action plans will be formed to actually achieve
(maintenance of) behavioural change. In addition, it is assumed
that this will eventually lead to a reduction in CVD risk (see figure
S2).
Intervention
The intervention consisted of a combination of tailored web-
based advice (PRO-FIT*advice) and face-to-face counselling com-
plemented with telephone booster sessions (PRO-FIT*coach). The
goal was to: 1) improve awareness of the cardiovascular disease
risk through an increase of specific knowledge, cues to action and
change in risk perception, 2) improve motivation with respect to
healthy behaviour through an increase of specific knowledge and a
change in attitude, self-efficacy and social influences, 3) adopt and
maintain a healthier lifestyle, with regard to physical activity,
saturated fat intake, fruit and vegetables intake, smoking and
compliance to statin therapy, and 4) lower the level of LDL-C and
other biological CVD risk indicators and thereby reducing the
CVD risk.
The intervention has been described in detail elsewhere [22].
Briefly, participants were encouraged to visit a weblink referring to
the project website, where generic CVD risk information was
presented, containing feedback on CVD risk behaviours, their
contribution to overall CVD risk, and cues on how to change
behaviours. Thereafter, participants could log on to a personal
account, consisting of six tailored advice modules on smoking,
physical activity, saturated fat intake, fruit intake, vegetables intake
and compliance to statin therapy. The module on compliance to
statin therapy was developed at the Rijksuniversiteit Groningen,
the Netherlands. The other modules were based on existing
tailored information modules of the ‘Healthy Life Check’ (in
Dutch: ‘Gezondlevencheck’) of the Netherlands Heart Foundation
[24]. The modules on fruit and vegetables were mainly based on
existing modules of the Live Healthy Coach (in Dutch:
Leefgezondcoach) of the Dutch Diabetes Federation, developed
at the Erasmus University Medical Centre in Rotterdam, the
Netherlands.
On-screen personalised feedback was tailored to personal
performance level (current lifestyle behaviour), awareness of one’s
own performance, as well as personal motivation to change,
outcome expectations, attitude and self-efficacy. Personalised
feedback to compliance to statin therapy was tailored on
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knowledge and personal beliefs about (the effect of) statin therapy,
potential side effects of the prescribed drug and current
compliance.
Subsequently, the participant and the personal coach further
established the level of the participant’s knowledge/awareness
about FH and CVD risk factors. Furthermore, the assessment(s)
and advice(s) within the participant’s personal PRO-FIT*advice
account were discussed and ambivalence and barriers related to
the recommended behaviour changes were explored based on
Motivational Interviewing (MI) techniques [25]. Further, an
additional one to five counsellor-initiated booster telephone
sessions were performed to further encourage the participant’s
behavioural changes. The two personal coaches had lifestyle
coaching and nursing/teaching backgrounds and had received an
additional 3-day MI workshop, incorporating both introductive
lessons and practical training sessions with professional actors.
Both participant and personal coach were not blinded for group
assignment and intervention implementation.
The control group received care as usual.
Measurements
Lifestyle related outcomes. The level of physical activity in
minutes of moderate to vigorous physical activity performed per
week, as well as whether participants either did meet or did not
meet the physical activity guideline of 30 minutes of moderate- to
vigorous physical activity on at least 5 days a week [26], was
measured by the Short QUestionnaire to ASsess Health-enhanc-
ing physical activity (SQUASH), which has been found to be fairly
reliable and reasonably valid [27].
Saturated fat, fruit and vegetables intake were measured by the
short Dutch questionnaire on total and saturated fat intake and on
fruit and vegetable intake, that have been validated as related to
seven day dietary records [28,29]. For the fruit and vegetable
questionnaire also biomarker validity has been established [30].
From this questionnaire, a score for saturated fat intake, ranging
from 0 (lowest) to 80 (highest) fat points was computed, as well as
servings of fruit and grams of vegetables per day. One fat point
equals 2 gram of saturated fat. Subsequently, it was assessed
whether a participant met the Dutch recommendations for daily
saturated fat intake, being #28 gram/day for men and #22
gram/day for women, as well as for daily fruit intake (2 servings/
day) and daily vegetable intake (200 gram/day) [31]. Smoking
behaviour was assessed by a self-reported measure, asking
participants if they were a current smoker, an ex-smoker, or a
never smoker. Consequently, they were categorized as either
smoker (if currently smoking) or non-smoker (if ex-smoker or never
smoker) [32].
The five-item Medication Adherence Report Scale (MARS-5)
was used to measure self-reported compliance to statin therapy,
which was found to have good reliability and validity [33]. Scores
on five items were combined to a total score ranging from 5
(lowest) to 25 (highest). The items referred to whether participants
always (1)/never (5) forget or stop their medication, decide to miss
out a dose, take less than instructed or alter the dose of their
medication without consulting a medical doctor and/or pharma-
cist. Based on former research, low compliance is suggested if one
or more doses are missing, thereby assuming an overestimation of
the actual compliance [34,35]. As a consequence, participants with
a score of 25 were categorised as compliant to statin therapy,
others (score,25) as non-compliant.
Other outcomes. Intention to change was assessed with a
self-report measure, asking participants whether they plan to
change behaviour X on a 5-point Likert scale (certainly yes (1) to
certainly no (5)) and how sure they are of this (absolutely sure (1) to
absolutely not sure(5)). Both scores were averaged and participants
were categorised into motivated (average score#2) or unmotivated
(average score.2) to change behaviour for each specific behaviour
[36].
Both height (in cm) and body weight (in kg) were measured
twice on calibrated scales. Body Mass Index (BMI) was calculated
from the average scores. LDL-C was measured with fasting finger
stick samples analysed on a Cholestech LDX desktop analyser
(Cholestech, Hayward, USA). The reproducibility and precision of
lipids measurement by the LDX analyser are within the guidelines
of the NCEP [37,38]. The Cholestech LDX analyser has been
validated for point-of-care lipid measurements in clinical practice
[39].
A process evaluation was carried out, taking into account the
process elements reach, dose (delivered and received) and fidelity.
The research methods of this evaluation, as well as the results and
discussion are extensively described elsewhere [40]. In short, reach
(the number of people with FH that took part in the project, as
well as how representative the participants in the intervention
group were for the study population and non-participants) was
assessed by consulting the StOEH client database, as well as the
PRO-FIT client database. The dose of all delivered elements of
the intervention was assessed by logs that were kept by the coaches
and the project database. Dose received, i.e. the way participants
used PRO-FIT*advice (% of participants that logged on, number
of modules finished), was assessed by means of log on rates and
website use data. Whether face-to-face counselling sessions were
implemented as planned according to MI guidelines (i.e. MI
fidelity) was assessed by two MI experts, following the Motiva-
tional Interviewing Treatment Integrity code (MITI 3.1.1.) [41].
Self-reported measures were collected through digital question-
naires that were sent by email. Body height, weight and lipid
measurements were conducted at the participants’ homes by a
research assistant.
Statistical analyses
Potential baseline differences were checked between interven-
tion and control group with linear and logistic regression analyses,
including group allocation as an independent variable, and the
following dependent variables: gender, age, education, BMI,
medication use, LDL-C and whether participants met the
recommendations on the different lifestyle behaviours at baseline.
In addition, differences between dropouts and non-dropouts
regarding the above-mentioned baseline characteristics were tested
with linear and logistic regression analyses as well. If baseline
differences were found, the variable concerned was included in
further analyses. Effect modification of the above-mentioned
variables and intention to change was checked and confirmed if
the p-value of the interaction term was ,0.05. Only in case of
significant effect modification, outcomes were presented per
category of the effect modifier (e.g. for women and men separately)
as well.
Primary, a complete case analysis was conducted at the
participant level, restricted to those who filled in questionnaires
at both baseline and follow-up. These numbers vary for different
outcome measures. Subsequently, an intention-to-treat analysis
was conducted, involving all participants who were randomly
assigned (n= 340). Missing data on physical activity, dietary
saturated fat, fruit and vegetable intake, smoking and compliance
to statin therapy were imputed using multiple imputations. Five
different datasets were created in SPSS (version 18.0) using Fully
Conditional Specification and Predictive Mean Matching proce-
dures. All available data on the above-mentioned lifestyle
outcomes, as well as on group allocation, gender, age, education,
Healthy Lifestyle Promotion in a High-Risk Sample
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BMI, medication use and LDL-C were included in the imputation
model. Thereafter the multiple datasets were analysed as described
below, using SPSS (version 18.0). Pooled estimates were computed
following the rules as described by Rubin [42]. As no major
differences were found, only the results of the complete case
analysis are presented.
In order to investigate whether the PRO-FIT intervention had
had an effect on physical activity, dietary saturated fat, fruit and
vegetable intake, smoking and compliance to statin therapy,
regression analyses were conducted. Linear regression analyses
were conducted, including group allocation as an independent
variable and the following continuous outcome measures as
dependent variables: saturated fat intake, fruit and vegetables
intake, physical activity, compliance to statin therapy). Because
data on physical activity were skewed, we log-transformed them
and conducted log-linear regression analyses. Binary logistic
regression analyses were conducted, including group allocation
as an independent variable and smoking as a dependent variable.
The post-test scores were regressed on study group and baseline
measure of the outcome variable.
Results
Baseline characteristics of participants
In Figure S1 the recruitment, participant and retention flow is
presented. As can be seen from Table 1, the participants were
equally distributed with regard to gender. Overall, a mainly
middle-aged, medium to highly educated, fairly overweight sample
participated in the project. The majority had an elevated LDL-C
and used cholesterol-lowering medication. Baseline differences
between control and intervention group were found for BMI
(b=21.10; CI 22.172 20.04). As a consequence, this variable
was included in the regression analyses. No differences were found
between dropouts and participants regarding the baseline charac-
teristics.
Effects on physical activity
No significant between-group differences were found regarding
physical activity. As can be seen from Table 2, after 12 months,
the control and intervention group performed more minutes of
moderate to vigorous physical activity per week. The majority of
both groups was compliant to the Dutch guideline of physical
activity at baseline (both 78%) and after 12 months (both 80%).
Effects on saturated fat and fruit and vegetable intake
After 12 months, the control and intervention group consumed
less fat points compared to baseline values. No significant between-
group effect was found. Gender appeared to be a significant effect
modifier (p = 0.03). Post-hoc analysis showed a significant
decreased fat consumption specifically among women in the
intervention group compared to the control group after 12 months
(see Table 2). In general, after 12 months, 13% more participants
in the intervention group met the recommendations for fat intake,
compared to 1% more in the control group.
No significant between-group differences were found regarding
fruit intake. A minimal change was seen in the amount of servings
of fruit per day consumed by both control and intervention group
after 12 months (see Table 2). In both control and intervention
group, the percentage of participants meeting the recommenda-
tions for fruit intake slightly increased (+2% and 7%).
No significant between-group differences were found regarding
vegetables intake. More grams of vegetables per day were
consumed in both control and intervention group after 12 months
(see Table 2). After 12 months, 12% more participants in the
control group met the recommendations for vegetable intake, as
opposed to 4% more participants in the intervention group.
Effects on smoking behaviour
No significant between-group effect was found on smoking
behaviour. A decrease in the overall percentage of smokers was
seen in both control and intervention group after 12 months (see
Table 2). Changes in smoking behaviour were similar in both
groups. The majority (control group: 80%; intervention group:
85%) continued not-smoking, and 13% (control group) and 10%
(intervention group) continued to be a smoker. Respectively 7%
(control group) and 5% (intervention group) quitted smoking in the
past year, and 1% in both groups started smoking.
Effects on compliance to statin therapy
No significant between-group effect was found on compliance to
statin therapy. Of the participants who used cholesterol lowering
medication at baseline, 44% of the participants in the control
group was categorised as compliant at baseline, associated with a
score of 25 on the MARS-5 questionnaire, compared to 38% in
the intervention group. After 12 months, an increase in
compliance was seen in both the control group and the
intervention group.
Process
A 34% (n= 181) representative proportion of the intended
intervention group was reached during the recruitment phase;
participants did not differ from non-participants (n = 623) on age,
gender and LDL-C levels. Of the participants, 95% received a
PRO-FIT*advice log on account, of which 49% actually logged on
and completed at least one advice module. Nearly all participants
received a face-to-face counselling session and on average, 4.2
telephone booster calls were delivered. None of the face-to-face
sessions were implemented according to MI guidelines.
Discussion
In this paper, we aimed to investigate the efficacy of an
individualised lifestyle intervention on physical activity, dietary
intake, smoking and compliance to statin therapy among people
with FH. After 12 months, improvements were seen in both
Table 1. Baseline characteristics of the control and
intervention group.
Control group Intervention group
Gender (% female; N) 56.3; N = 159 57.1; N = 181
Age (years, mean 6 SD; N) 45.9 (13.0); N = 159 44.7 (12.9); N = 181
Education1 (%; N)
low 3.6 3.1
medium 62.8 58.2
high 33.6; N = 137 38.7; n = 163
BMI (kg/m2, mean 6 SD; N ) 27.1 (5.3); N=159 26.0 (4.7); N=181
Medication use (% yes; N) 69.6; N = 159 68.8; N = 181
LDL-C (mmol/l, mean 6 SD; N ) 3.7 (1.2); N = 130 3.7 (1.3); N = 146
1Classification according to National Monitor Public Health: www.
monitorgezondheid.nl.
N = sample size; SD = standard deviation; BMI = body mass index; Significant
differences between control and intervention group (P,0.05) are printed in
bold font.
doi:10.1371/journal.pone.0050032.t001
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control and intervention group in physical activity, saturated fat
intake, fruit and vegetable intake, smoking and compliance to
statin therapy. Although most changes were more pronounced
among participants in the intervention group, the between-group
differences were small and not significant. Post-hoc analyses
showed a significant decrease in the intervention group in
saturated fat intake among women.
This lack of effects is in contrast with the latest evidence in the
field of computer-tailored promotion of healthy lifestyle behav-
iours; recent reviews and meta-analyses indicate that such tailored
interventions are likely to be effective [18,25,43–47] [48–50].
However, evidence on the effects of such and other lifestyle
interventions in a FH population is scarce. In a review on dietary
interventions in a FH population, Shafiq and colleagues emphasise
the need for large, parallel randomised controlled trials, since no
reliable conclusions could be drawn from the included studies [51].
Until now, no indisputable effects have been published so far.
Table 2. Lifestyle behaviours at baseline and follow-up and intervention effects from linear or logistic regression analyses.1
Control group Intervention group
Mean (SD);N Mean (SD);N b 95% CI
MVPA2 (min/wk)
Baseline 363.1 (3.5); N = 146 422.0 (3.1); N = 171
12 months 428.0 (3.7); N = 146 501.0 (3.3); N = 171
Difference +64.9 +79.0 1.113 20.12–0.33
Saturated fat intake (fat points/day)
Baseline 14.3 (4.9) N = 146 15.4 (4.8) N = 171
12 months 13.7 (4.6) N = 146 14.0 (5.0) N = 171
Difference 20.6 21.4 20.61 21.35–0.14
Fruit intake (servings/day)
Baseline 1.4 (1.1); N = 145 1.5 (1.3); N = 169
12 months 1.4 (1.1); N = 145 1.6 (1.1); N = 169
Difference +0.0 +0.1 0.05 20.12–0.22
Vegetables intake (grams/day)
Baseline 151.2 (77.8); N = 144 162.1 (75.8); N = 169
12 months 163.4 (77.2); N = 146 171.5 (76.6); N = 169
Difference +12.2 +9.4 3.26 29.78–16.29
Smokers (%)
Baseline 15.2; N = 145 18.3; N = 171
12 months 10.2; N = 146 13.5; N-171
Difference 25 24.8 OR= 1.15 0.39–3.33
Compliant to statin therapy (%)4
Baseline 44.4; N = 99 38.1; N = 118
12 months 51.4; N = 105 44.5; N = 119
Difference +7.0 +6.4 OR= 0.99 0.51–1.94
Post-hoc analyses
Saturated fat intake (fat points/day) in
men
Baseline 16.3 (5.3); N = 63 16.7 (4.9); N = 73
12 months 15.2 (4.5); N = 63 15.5 (5.2); N = 73
Difference 21.1 21.2 20.06 21.30–1.16
Saturated fat intake (fat points/day) in
women
Baseline 12.8 (3.9); N = 82 14.4 (4.5); N = 98
12 months 12.6 (4.4); N = 83 12.8 (4.6); N = 98
Difference 20.2 21.6 21.03 21.98–20.08
1Differences between control and intervention group after 12 months are tested through linear of logistic regression analyses, controlled for baseline values and
baseline BMI. N = sample size; SD = standard deviation; b/OR = beta or Odds ratio as effect indicators from linear or logistic regression analyses; 95% CI = 95% confidence
interval as effect indicator from linear or logistic regression analyses; Significant differences between control and intervention group (P,0.05) printed in bold font.
2MVPA=Physical activity with moderate to vigorous intensity; means are geometric means;
3Log-linear regression was conducted;
4Assessed with the MARS-5 questionnaire, a score = 25 is defined as compliant, ,= 24 is defined as noncompliant.
Since no major differences were found between intention-to-treat analysis and complete case analysis, only the results of the complete case analysis are presented.
doi:10.1371/journal.pone.0050032.t002
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It may be that the intervention reach and true exposure (dose
received) was insufficient to initiate behaviour changes. The
content of the intervention was largely based on earlier tailored
interventions, that were effective on behaviour changes, and our
process evaluation indicates that participants were sufficiently
exposed to the intervention. However, the results also indicate that
only half of the participants logged on at the PRO-FIT*advice
website and completed at least one of the advice modules, and that
face-to-face counselling sessions were delivered with low MI
fidelity. Mixed evidence has been published on computer-tailored
interventions addressing more than one lifestyle behaviour. In
their latest review, Sweet and colleagues concluded that single
health behaviour interventions are more effective at changing
specific health behaviours than multiple-behaviour interventions
[52]. Further, it appears from literature that multiple-behaviour
interventions may be burdensome for some individuals, and
advices may be too long [53–55]. Regarding the low MI fidelity, it
has often been reported that skills required for effective MI may
take longer to develop than the 3-day MI workshop in our project
[56,57]. Probably, the provided MI workshop was not sufficient
and more thorough monitoring and supervision of counselling
skills during the intervention should have been built in.
The lack of large improvements in both control and interven-
tion group, might be caused by the relatively healthy lifestyle of
our population. Results showed that the majority of the people
with FH in this project already met the recommendations on
physical activity and smoking behaviour at baseline (physical
activity: 78%; non-smokers: 81–85%). However, this was the case
for both control and intervention group. On this point, the FH
population obviously differed from the general Dutch population,
as survey data show that only 53% of the Dutch general
population is sufficiently physically active and 73% of all Dutch
adults are non-smokers [58] [26]. Though, there was much room
for improvement with regard to saturated fat and fruit and
vegetable consumption. Only 49–57% of our study population met
the Dutch recommendations on saturated fat consumption, and
only one third on fruit and vegetable consumption.
The baseline self-reported compliance to statin therapy in our
project (38–44%) is comparable to those reported in the literature.
Our results showed no significant intervention effect. According to
recent reviews, the effects of compliance-improving interventions
are generally small [34,59]. About 50% of the interventions
proved to be efficacious, and effects on treatment outcomes (p.e.
LDL-C) were often absent. So far, little is known about the
determinants of compliance [34]. Julius and colleagues recom-
mended assessing patients’ motivation to take prescribed medica-
tions, and to identify and address potential barriers to compliance
[60].
To our knowledge, the PRO-FIT intervention is the first to
evaluate the effects of an innovative lifestyle intervention on
multiple lifestyle behaviours among people with FH. The RCT
was conducted in a sample representative for the general FH
population with a small drop-out rate. The intervention is
innovative in combining three communication channels: the
individualised web-based approach added by the social interaction
of the face-to-face and telephone coaching sessions. So far, few
studies have evaluated the effects of an intervention that had
combined web-based computer-tailored lifestyle education and
motivational interviewing techniques on multiple lifestyles [61–
63]. Thereby, the step-wise approach of raising awareness first,
then giving tailored feedback and thereafter motivating people
towards behavioural change, is thoroughly described and based on
a firm theoretical framework [22,23]. Moreover, from the process
measures reach and dose it can be said that the implementation of
the intervention was feasible. Confidence in the validity of our
findings is increased by the parallel randomised study design and
absence of differential attrition.
This project also had limitations. Behaviour is multi-dimen-
sional and complex to measure by self-report. The use of
inappropriate or crude measures has serious implications and
could likely have led to misleading results, for instance an
underestimation of effect sizes. Although fairly reliable and valid
questionnaires were used, the choice of a (self-report) measure
often remains a compromise between the research aim, accuracy
level and feasibility [64].
Despite randomization of 4 clusters of family members living in
the same household, communication among family members of
control and intervention group was unavoidable. The Dutch
screening program works cascade-wise; once a person is diagnosed
(the index patient), pedigrees are consulted to trace other
potentially FH positive family members. In a relative small
country such as the Netherlands, families appeared to be wide-
spread and overlapping each other, making it rather challenging to
prevent communication, which therefore should be taken into
account when interpreting the results.
Conclusions
In conclusion, this project suggests that in general individually
tailored feedback is not superior to generic feedback regarding
changes in multiple lifestyle behaviours in people with FH.
Women aged 18–40 years in the intervention group consumed
significantly less saturated fats, and compliance to statin therapy
significantly improved among unmotivated medication users in the
intervention group. These results should be carefully interpreted,
due to post-hoc analyses of relatively small subgroups. Research is
needed to gain more insight in the characteristics of this specific
high-risk population, for instance risk perceptions and determi-
nants of behaviour, such as self-efficacy, attitude, motivation and
social influence. The effects of the small lifestyle changes on CVD
risk remains (and is due) to be investigated.
In practice, it is crucial to achieve an optimal received dose of a
computer-tailored intervention, by e.g. reducing the burden of
filling in (screening) questionnaires to a minimum in order to keep
participants motivated, e.g. by creating a joint questionnaire, for
both evaluative and tailoring purposes. Thereby, it is known that
incorporating iterative feedback and interactive website compo-
nents are positively associated with exposure to web-based
interventions [65]. Further, MI training of counsellors should be
more extensive, incorporating more thorough monitoring and
supervision of counselling skills.
Supporting Information
Figure S1 Recruitment, participant and retention flow.
People diagnosed with FH from January 1st 2007 to April 15th
2009, aged from 18 to 70 years, with a LDL-C level.75th
percentile (age and gender specific), with access to internet,
sufficient fluency in Dutch and residency ,150 km radius from
Amsterdam were considered as eligible for participation and
recruited from the national cascade screening programme of the
Foundation for the Identification of Persons with Inherited
Hypercholesterolemia (StOEH). Invitation brochures were send
to 986 people. The recruitment period lasted 6 months and
resulted in 340 participants. Three hundred and eighteen
participants (94%) completed the baseline and follow-up ques-
tionnaires. Missing data on physical activity, saturated fat intake,
fruit and vegetables intake, smoking and compliance to statin
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therapy were imputed using multiple imputations, allowing an
intention-to-treat analysis based on 340 participants.
(TIF)
Figure S2 The I-Change model 2.0. The I-Change model
assumes that the behavioural change process can be distinguished
in three phases: 1) Awareness, 2) Motivation and 3) Action.
Hypothetically, due to gained knowledge and awareness of one’s
CVD risk, a participant will become motivated to change lifestyle
behaviour(s), and subsequently, implementation intentions and
action plans will be formed to actually achieve (maintenance of)
behavioural change. In addition, it is assumed that this will
eventually lead to a reduction in CVD risk.
(TIF)
Protocol S1 Trial protocol.
(PDF)
Checklist S1 CONSORT checklist.
(DOC)
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